2012 Annual Report - National Breast Cancer Coalition

THE NATIONAL BREAST CANCER COALITION:
1991-2020
Founded in 1991, the National Breast
Cancer Coalition’s (NBCC) mission is
to eradicate breast cancer through
the power of action and advocacy.
On September 20, 2010, NBCC set a deadline and launched a plan of action to reach its mission: Breast Cancer Deadline
2020®—knowing how to end breast cancer by January 1, 2020.
NBCC increases federal funding for breast cancer research; monitors how research funds are spent; expands access to
quality health care for all; and ensures that trained advocates influence all decision making that affects breast cancer.
NBCC links hundreds of organizations and tens of thousands of individuals from across the country into a dynamic, diverse
coalition that gives breast cancer a meaningful voice in Washington, DC and state capitals, in laboratories and health care
institutions, and in local communities everywhere.
Our activism has generated more than $2.77 billion new dollars for breast cancer research. Our research initiatives and
advocacy helped bring about new models of research, including a significant breakthrough in breast cancer research and
care—the first targeted therapy for a particularly aggressive form of breast cancer.
Our vision and advocacy led to the first-ever system of access to care for thousands of low-income women with breast and
cervical cancer. And we’ve trained more than 11,000 advocates who challenge the status quo and demand more wherever
breast cancer decisions are made—from hospital boardrooms to Capitol Hill.
There was a time when breast cancer was virtually ignored by those with the power to do something about it. Today we are
holding these key stakeholders—and ourselves—accountable to Breast Cancer Deadline 2020®.
FROM THE PRESIDENT:
We are getting there. We all knew that Breast Cancer Deadline 2020® was a daunting goal. But we also knew that the National Breast
Cancer Coalition (NBCC) has a history of taking on daunting challenges and succeeding. 2012 was a year of accomplishments for
NBCC that has brought us closer to our deadline goal. How can we possibly miss? NBCC has amazing advocates, and committed and
passionate supporters. With all of that behind us, we will achieve our mission.
It will not be easy. As we all know, this year 425,000 women around the world will die of breast cancer and it is estimated that, at the
current rate of progress, by 2030 that number will be nearly 750,000. Each day 108 women die in this country alone. That loss of life
tells us that whatever progress has been made is tragically insufficient and that without the deadline we will be far from success.
Throughout our history, NBCC has worked side by side with scientists, advocates, government and industry to end breast cancer.
Together we have successfully increased federal funding for research and helped change public policy. We know that conventional,
conservative approaches to breast cancer will not help us achieve our Breast Cancer Deadline 2020® goal—knowing how to stop women
and men from getting breast cancer and from dying of it.
The decades of investments in breast cancer research and health care have brought about new tools, technology and knowledge that
now must be harnessed to the larger goal of ending breast cancer and saving lives.
As we lay out in our 2012 Annual Report, we have a detailed strategic plan of action to achieve Breast Cancer Deadline 2020®. We have
brought together advocates and researchers who are working collaboratively on our Artemis Project® for a Preventive Breast Cancer
Vaccine. We continue to educate new advocates through Project LEAD® and we are reaching thousands of new advocates around the
world with our new Online Center for NBCC Advocacy Training. Our grassroots are taking action and have developed blueprints for
action to be implemented their states. In November 2012, we announced former US President Bill Clinton will serve as the Honorary
Chair of Breast Cancer Deadline 2020®. And NBCC took the lead inviting breast cancer organizations from across the country to sign
a petition to Genentech, urging them to do what is in the best interest of women as they develop T-DM1 clinical trials for early breast
cancer. Nearly 60 organizations signed onto that petition. And 75,000 NBCC advocates asked the President to make Breast Cancer
Deadline 2020® a national priority.
There is so much more to do. And we cannot do it alone. We will lead collaborations, change the
conversation, and empower and organize the public to get behind Breast Cancer Deadline 2020®.
And with your help we will galvanize the scientists, industry, policy makers and other leaders to do
their part so we can end breast cancer everywhere for everyone.
Sincerely,
Fran Visco
President, National Breast Cancer Coalition
JANUARY 1,
2020
We Will Know How to End Breast Cancer
As the calendar turned to another year closer to the deadline, the National
Breast Cancer Coalition got another year closer to knowing how to end
breast cancer by the end of the decade.
3
PRIMARY STRATEGIES DESCRIBED IN BLUEPRINT
FOR BREAST CANCER DEADLINE 2020®
The Blueprint, released in August
2012, details NBCC’s strategic plan
of action to harness the energy,
resources and leadership around
the world to achieve its mission
using three primary strategies:
Research needed to end breast cancer
Global access to necessary information and lifesaving interventions; and
The influence of leaders everywhere in the fight to end breast cancer.
2nd
The second annual meeting of NBCC’s Artemis
Project® for a Preventive Breast Cancer Vaccine
ANNUAL MEETING OF THE
PROJECT
convened in California the first weekend in March. Advocates and researchers from institutions
including Cold Spring Harbor Laboratory, City of Hope Beckman Research Institute, the Mayo Clinic,
University of Pennsylvania, the Whitehead Institute and several others, came together for three days
to collaborate on the challenges and opportunities related to the development of a breast cancer
preventive vaccine.
POTENTIAL BREAST CANCER
TARGETS TO BE ANALYZED
FOR PREVENTIVE VACCINE:
50-100
Through the generous support of National Philanthropic Trust (NPT), NBCC awarded
a seed grant to Dr. Paul Spellman and Dr. Joe Gray of Oregon Health and Science
University to identify possible vaccine targets using existing and developing human
genomic data within different breast cancer subtypes. The analysis will generate a
prioritized list of 50-100 potential breast cancer specific targets to be considered for
incorporation into a preventive vaccine.
PROGRESS REPORT
2020
2019
2018
2017
2016
2015
2014
Breast Cancer
Deadline 2020®
2nd Annual
Progress Report
2013
2nd
2012
2011
NBCC released its 2nd Annual Progress Report
summarizing the state of breast cancer and
the status of Breast Cancer Deadline 2020®,
NBCC’s campaign to know how to end
the disease by January 1, 2020. The report
updated the 2011 Baseline Report, which
described the lack of adequate progress
despite billions of dollars in public and
private resources directed at the disease.
ANNUAL PROGRESS
REPORT RELEASED
60
NEARLY
NEW ADVOCATES GRADUATE
FROM PROJECT LEAD® INSTITUTE
Nearly 60 advocates attended the 2012 Project LEAD® Institute
to study molecular biology, genetics, mutations, epidemiology,
research design and much more during the five and a half day
course. As NBCC President Fran Visco explained in her welcome
remarks, advocates with the critical ability to ask the right
questions and work alongside scientists to help focus research are
a crucial part of the strategy for achieving the mission of Breast
Cancer Deadline 2020®. Throughout the week-long program,
students heard lectures from a renowned group of scientists,
clinicians and researchers from the National Institutes of Health
(NIH), Massachusetts General Hospital, University of Buffalo,
Roswell Cancer Center, UCLA, City of Hope, Amherst College and
the Scripps Research Institute.
THE CENTER FOR NBCC
ADVOCACY TRAINING
REACHES
1,000s
Debuting in October, NBCC launched the Online Center for
NBCC Advocacy Training to give advocates from around the
world an opportunity to re-live or experience for the first
time some of the great highlights and sought-after speakers
featured at NBCC’s events. Advocates can now hear some
of the best thinkers in the world of breast cancer who have
presented at NBCC’s Project LEAD® courses, Advanced
Topics sessions, Advocate Summits and more.
During the 2012 Annual Advocate Summit, each advocate attended a State Action Planning
Workshop—a hands-on training that resulted in state blueprints for year two work in
support of Breast Cancer Deadline
2020®. Advocates in 35 states, and
the District of Columbia, developed
regional plans that focused on
increasing the number of signatures
35
on NBCC’s Petition to the President
and organizational endorsements of
Breast Cancer Deadline 2020®.
STATES TAKING
ACTION ON
BREAST
CANCER
DEADLINE
2020®
MORE THAN
The NBCC Annual Advocate Summit, formerly
the
Annual
Advocacy
Training
Conference,
kicked off the event with an inspiring
and energizing opening rally. More
than 600 advocates shared their
Breast Cancer Deadline 2020®
work with those in attendance.
The plenary sessions reflected a
a
thought-provoking and exciting
mix of topics focused on research
updates
from
year
one
of
Breast Cancer Deadline 2020®,
a discussion of what the breast
cancer community could learn from
ADVOCATES ATTEND
THE 2012 ANNUAL
ADVOCATE SUMMIT
other social change movements, the
barriers standing in the way of progress, and
a political analysis of what it will take to make
ending breast cancer a priority during the 2012
Presidential election cycle.
Representing nearly every state in
the
nation,
50
grassroots
leaders
came to Washington in March for an
intensive two-day training program.
These grassroots leaders are trained in
advocacy techniques and public policy.
GRASSROOTS
LEADERS GET
TRAINED AS
TEAM LEADERS
Lobby Day 2012 was another hugely successful day for NBCC
advocates, who came out in force to seek support for NBCC’s
2012 public policy agenda. Advocates’ primary focus was to
substantially increase the number of cosponsors on H.R. 3067,
the Accelerating the End of Breast Cancer Act. Immediately
before our May Lobby Day, there were 127 cosponsors. By the
month’s end, we had reached 220 cosponsors, more than half
the members of the House of Representatives, including 29 of
the 54 critically important members of the House Energy and
Commerce Committee which had jurisdiction over the bill.
400+
CONGRESSIONAL MEETINGS ON
LOBBY DAY
About one month after NBCC’s Lobby Day, the Accelerating the End of Breast Cancer Act
was introduced by Senator Sheldon Whitehouse (D-RI), along with Senators Grassley (RIA), Brown (D-OH), Collins (R-ME), Shaheen (D-NH), Murkowski (R-AK), Warner (D-VA) and
Heller (R-NV) as companion legislation to the bill in the House of Representatives which
was introduced in 2011 by Reps. Karen Bass (D-CA-33) and Rep. Charlie Bass (R-NH-2).
The legislation is a vital component of Breast
Cancer Deadline 2020® and focuses on ending
breast cancer by identifying strategies for the
primary prevention of the disease and identifying
methods to prevent breast cancer metastasis,
thereby saving lives.
SENATORS
INTRODUCE THE
ACCELERATING
THE END OF
BREAST CANCER
ACT AS COMPANION
LEGISLATION TO THE
HOUSE BILL
In November, NBCC announced that President Bill Clinton will
serve as the Honorary Chair of Breast Cancer Deadline 2020®—
the Coalition’s strategic plan of action to end breast cancer by
January 1, 2020.
“It’s time to give breast cancer a deadline,” said President Clinton.
“That’s why I applaud the National Breast Cancer Coalition’s
ambitious campaign to end breast cancer by 2020. The stakes are
too high, the losses have been too great to let another decade go
by without ending breast cancer.”
President Clinton has a long history of collaboration with NBCC.
His commitment to NBCC’s mission to end breast cancer began
with his administration and continues to the present time.
1
FORMER US
PRESIDENT
TO SERVE AS
HONORARY CHAIR
OF THE GLOBAL
CAMPAIGN,
BREAST CANCER
DEADLINE 2020®
PETITION TO GENENTECH: DO
WHAT’S
October 22, 2012
To: Ian T. Clark, CEO
Sandra Horning, M.D., SVP Global
56
BEST FOR WOMEN
Head, Clinical Research Hematology/
Oncology
We urge Genentech to do what is
in the best interest of women diagnosed
with breast cancer. We are breast
patients and advocates who urge
cancer
Genentech to fulfill the promise
of targeted therapy and include
treatment arm in the clinical trials
a non-systemic
to evaluate the adjuvant/neo-adjuvant
use of T-DM1 for HER2+ early breast
We also ask that you include non-anthracyc
cancer.
line regimens for those arms which
These trials represent an unprecedented
do include systemic chemotherapy.
opportunity for at least a subset of
women to move their care toward
treatment, without sacrificing treatment
less toxic
benefit.
These decisions must be considered
in the context of the reality for women.
We know that a significant number
diagnosed with early breast cancer
of women
are overtreated. And we know that
the number of these women is increasing,
population is aging and more women
as the
are being diagnosed. We also know
that there is no absolute cure for breast
and that our current treatments do
cancer
not work for many women. It is critically
important that while steps are being
to improve the benefit from treatment,
taken
steps are also taken to reduce the
harms from treatment. We do not
Genentech squander this opportunity
want to see
to move patient care forward on both
fronts.
The promise of targeted cancer
treatment, and particularly with drug-antibody
effective treatment that is less toxic.
conjugates such as T-DM1, is more
The promise is to save lives with
fewer long-term health consequences
promise of targeted cancer treatment
. But this
will never be realized without taking
bold steps in clinical trial design
must move away from the systemic,
now. We
toxic therapy and “add-on” model
in breast cancer clinical trials and
treatment.
A trial of T-DM1, a novel drug, which
includes a chemotherapy agent that
is not dispersed systemically, provides
perfect opportunity to move away
from a more toxic regimen. With T-DM1,
the
women will still get chemotherapy.
old “add-on” approach will not deliver
Using the
on the promise of real progress for
patients. This is an opportunity to
model for research on future conjugates
provide a
in breast cancer. We must act now
and get it right.
And for those arms within the trial
that will include systemic chemotherapy
treatment, non-anthracycline based
are best for women. No prospective
regimens
randomized clinical trial has shown
anthracyclines to be more effective
chemotherapies, while the toxicities
than
other
are significant, including an increased
risk of leukemia and harm to the
Considering non-anthracycline regimens
heart.
seems particularly important now
as we have evidence of a dramatic
in their use in the community. The
decline
“standard of care” within the clinical
trial design used to evaluate any
should reflect the actual care being
new agent
given in the community in order to
give relevant and meaningful results
to patients.
We are hopeful that T-DM1 will provide
meaningful benefit to those with
early breast cancer, but we are also
hopeful that Genentech will do what
equally
is best for women and will use this
opportunity to decrease the harms
experience from treatment for early
women
breast cancer.
ORGANIZATIONS JOINING THIS
National Breast Cancer Coalition
Adelphi NY Statewide Breast Cancer
Hotline & Support Program
AdvancedBC.org
Advocates for Breast Cancer, Inc.
African American Breast Cancer Alliance,
Inc.
Alamo Breast Cancer Foundation
Ann’s Place
Annie Appleseed Project
Between Women, Inc.
Breast Cancer Alliance of Greater Cincinnati
Breast Cancer Care & Research Fund
Breast Cancer Coalition of Nevada
Breast Cancer Coalition of Rochester
California Breast Cancer Organizations
Cancer Support Network of Zambia
Capital Region Action Against Breast
Cancer (CRAAB!)
CARE Advocates
Causes for a Cure
PETITION
Cedar Valley Cancer Committee’s Beyond
Pink TEAM
Circle of Hope
Colorado Breast Cancer Coalition
Delaware Breast Cancer Coalition
Dr. Susan Love Research Foundation
END Breast Cancer Illinois
Georgia Breast Cancer Coalition Fund
Inflammatory Breast Cancer Research
Foundation
Iowa Breast Cancer Edu-Action
Linda Creed Breast Cancer Foundation
Los Angeles Breast Cancer Alliance
Louisiana Breast Cancer Task Force
Maine Breast Cancer Coalition
Metropolitan Washington, DC Chapter
of NBCC
Michigan Breast Cancer Coalition
Minnesota Breast Cancer Coalition
National Women’s Health Network
New Hampshire Breast Cancer Coalition
North Carolina Breast Cancer Advocacy
Network
Northern Ohio Breast Cancer Coalition
Fund
ORGANIZATIONS
URGE GENENTECH TO DO
WHAT’S RIGHT FOR WOMEN
Nueva Vida
Oregon Breast Cancer Network
Pennies in Action
Rhode Island Breast Cancer Coalition
SHARE Self-help for Women with Breast
or Ovarian Cancer
Saul and Joyce Brandman Breast Center
Sisters’ Journey
South Dakota Breast Cancer Advocacy
St. Louis Breast Cancer Coalition
Texas Breast Cancer Coalition
The Metastatic Breast Cancer Network
Virginia Breast Cancer Foundation
Viva Las Chicas
Washington State Breast Cancer Deadline
Action Network
Wisconsin Breast Cancer Coalition
Women of Color Breast Cancer Survivors’
Support Project
You Can Thrive! Foundation
Young Survival Coalition
NBCC took the lead, inviting breast cancer organizations
across the country to sign a petition to Genentech urging
them to do what is in the best interest of women as they
develop T-DM1 clinical trials for early breast cancer. The drug
being tested—T-DM1—may have potential as a new model
that could be effective and at the same time spare patients
the long-term toxic effects of systemic chemotherapy.
T-DM1 is not a new drug but a new way to deliver a
combination of targeted therapy and chemotherapy with
minimal systemic effect.
WE ENDORSE
BREAST CANCER
DEADLINE 2020®
By the end of 2012, 265 state and local organizations representing
nearly all 50 states, as well as a half dozen countries endorsed Breast
Cancer Deadline 2020®. NBCC’s grassroots network continues its
265
strong focus on soliciting likely supporters such as breast cancer
support groups and women’s health and advocacy groups.
ORGANIZATIONS
GLOBALLY
ENDORSE
BREAST CANCER
DEADLINE 2020®
PETITION
IT’S TIME TO END BREAST CANCER. SIGN ON.
TO THE PRESIDENT OF THE UNITED STATES:
This year, nearly 40,000 women will die of breast cancer in the U.S.; it will take the lives of almost 500,000 women
worldwide. This nation has invested billions of dollars in breast cancer research and technology yet the statistics have
not changed significantly over the past decades. Our investments have brought us to the point where we have the
knowledge, technology and tools to make a real difference. It is time to leverage those investments to end this disease.
The National Breast Cancer Coalition set a deadline: Breast Cancer Deadline 2020®, the end of breast cancer by January
1, 2020. In 1961, President Kennedy challenged this country to put a man on the moon by the end of the decade, and the
Apollo program was born. Deadlines matter! Now we need to similarly harness our nation’s drive, ability and passion to
save millions of lives.
We, women and men across this country who want to see an end to breast cancer, look to you to once again bring this nation’s leadership,
intellectual and creative forces to bear on a matter of utmost importance to everyone, around the world. We ask for your public commitment
to work with the National Breast Cancer Coalition to end breast cancer by January 1, 2020 by supporting Breast Cancer Deadline 2020®.
Are you with us?
Sign the Petition at BreastCancer Deadline 2020.org/Presidential Petition
"
PETITION
IT’S TIME TO END BREAST CANCER. SIGN ON.
TO THE PRESIDENT OF THE UNITED STATES:
This year, nearly 40,000 women will die of breast cancer in the U.S.; it will take the lives of almost 500,000 women
worldwide. This nation has invested billions of dollars in breast cancer research and technology yet the statistics have
not changed significantly over the past decades. Our investments have brought us to the point where we have the
knowledge, technology and tools to make a real difference. It is time to leverage those investments to end this disease.
The National Breast Cancer Coalition set a deadline: Breast Cancer Deadline 2020®, the end of breast cancer by January
1, 2020. In 1961, President Kennedy challenged this country to put a man on the moon by the end of the decade, and the
Apollo program was born. Deadlines matter! Now we need to similarly harness our nation’s drive, ability and passion to
save millions of lives.
We, women and men across this country who want to see an end to breast cancer, look to you to once again bring this nation’s leadership,
intellectual and creative forces to bear on a matter of utmost importance to everyone, around the world. We ask for your public commitment
to work with the National Breast Cancer Coalition to end breast cancer by January 1, 2020 by supporting Breast Cancer Deadline 2020®.
Are you with us?
Sign the Petition at BreastCancer Deadline 2020.org/Presidential Petition
"
PETITION
IT’S TIME TO END BREAST CANCER. SIGN ON.
TO THE PRESIDENT OF THE UNITED STATES:
This year, nearly 40,000 women will die of breast cancer in the U.S.; it will take the lives of almost 500,000 women
worldwide. This nation has invested billions of dollars in breast cancer research and technology yet the statistics have
not changed significantly over the past decades. Our investments have brought us to the point where we have the
knowledge, technology and tools to make a real difference. It is time to leverage those investments to end this disease.
The National Breast Cancer Coalition set a deadline: Breast Cancer Deadline 2020®, the end of breast cancer by January
1, 2020. In 1961, President Kennedy challenged this country to put a man on the moon by the end of the decade, and the
Apollo program was born. Deadlines matter! Now we need to similarly harness our nation’s drive, ability and passion to
save millions of lives.
We, women and men across this country who want to see an end to breast cancer, look to you to once again bring this nation’s leadership,
intellectual and creative forces to bear on a matter of utmost importance to everyone, around the world. We ask for your public commitment
to work with the National Breast Cancer Coalition to end breast cancer by January 1, 2020 by supporting Breast Cancer Deadline 2020®.
Are you with us?
Sign the Petition at BreastCancer Deadline 2020.org/Presidential Petition
During the 2012 election cycle, NBCC and its advocates
worked tirelessly to educate the candidates on the
importance of ending breast cancer and making it a national
priority. Thousands of NBCC advocates reached out to
the candidates and asked them to support Breast Cancer
Deadline 2020®. Leading up to the Presidential election, and throughout the
75,000
campaign season, 75,000 individuals from across the country signed petitions
to send a strong message to the future President echoing this request.
NBCC ADVOCATES ASK PRESIDENT TO
SUPPORT BREAST CANCER DEADLINE 2020®
MORE
THAN
300
GUESTS HONOR
STEPHANIE SPERBER, PRESIDENT, UNIVERSAL
PARTNERSHIPS AND LICENSING AT LES GIRLS 12
NBCC honored Stephanie Sperber, President, Universal
Partnerships and Licensing for her commitment to
ending breast cancer and for her work in support
of NBCC at the Les Girls 12 cabaret. More than 300
guests attended the event at the Avalon Hollywood
in October. Once again, Les Girls was a fantastic show
with an incredible line up of performers, and hosts
Monica Potter and Peter Krause. NBCC is grateful to
Stephanie, the Les Girls Committee, and the many
stars who donated their time and talent to the event.
3
HONORED AT NBCC’S
17TH ANNUAL NY GALA
NBCC’s 17th Annual New York Gala took place on November
28 at Gotham Hall. NBCC’s grassroots advocates who were
recipients of the 2012 Advocacy Awards, N. Beth Emery
and Julia Moore, exemplify the spirit of NBCC—passionate,
relentless and mission-driven. NBCC also honored Eileen R.
Heisman, President & CEO of National Philanthropic Trust
with the NBCC Leadership Award for her commitment to
ending breast cancer. These awards honor individuals who
have made a true difference in the world of breast cancer.
NBCC is pleased to recognize them for their leadership and
the extraordinary work they have done to help NBCC reach
its goal of knowing how to end breast cancer by January
1, 2020.
1,000,000s
& 1,000,000s
REACHED THROUGH
INTERVIEWS IN MAJOR
NEWS OUTLETS
1.87 million daily readers for the New York Times; 3.2 million
readers globally for USA Today; 21 million viewers around the world
through Reuters; more than 18 million readers internationally on
The Daily Beast; 37 million reached through Fran Visco’s column
on Huffington Post; and 87 million viewers reached as Visco and
Actress Peri Gilpin appeared on The Marie Show. With additional
interviews on NPR, PBS, and local CBS and Fox affiliates, NBCC
continued to shift the public dialogue about breast cancer from
awareness and screening to prevention and saving lives.
Breast Can
cer Deadlin
e 2020®
is Social!
Facebook.co
NBCC FOLLOWERS
ON SOCIAL MEDIA
m/StopBreast
Twitter.com/D
eadline2020
With nearly 50,000 followers on Facebook, Twitter
and YouTube, NBCC continues to inform and
activate the public on the issue of breast cancer.
NBCC’s website and social media pages deliver
information about the current state of breast
cancer and the Breast Cancer Deadline 2020®
plan of action to end the disease.
Cancer
YouTube.co
BreastCance m/
rDeadline
2012
NATIONAL BREAST CANCER COALITION FUND
ASSETS & LIABILITIES
ASSETS
Cash & Cash Equivalents
Accounts Receivable
Prepaid Expenses
Investments
Property & Equipment (net)
Deposits
TOTAL ASSETS
155,480
3,339,204
67,899
1,242
87,652
38,167
3,689,644
LIABILITIES
TOTAL LIABILITIES
1,415,828
NET ASSETS
TOTAL NET ASSETS
2,273,816
TOTAL LIABILITIES & NET ASSETS $3,689,644
NATIONAL BREAST CANCER COALITION FUND
2012 PUBLIC SUPPORT & OTHER REVENUE:
$5,626,206
OTHER REVENUE
SPECIAL EVENTS (NET)
15%
2%
RESTRICTED GRANTS
CORPORATIONS
& FOUNDATIONS
49%
16%
INDIVIDUALS
18%
NATIONAL BREAST CANCER COALITION FUND 2012 EXPENSES:
$5,107,049
EDUCATION & TRAINING
34%
PUBLIC INFORMATION,
EDUCATION & OUTREACH
FUNDRAISING
13%
14%
MANAGEMENT & GENERAL
7%
OTHER PROGRAMS
1%
GRASSROOTS ADVOCACY FIELD
NETWORK DEVELOPMENT & SUPPORT
6%
CATALYTIC RESEARCH
& COLLABORATIONS
PUBLIC POLICY
12%
13%
2012
PRESIDENT’S COUNCIL
Anonymous (7)
Susanna Lachs Adler & Dean Adler
Sarah Allen
Madeline & Stephen Anbinder
Amy L. Applebaum
Susan & Robert Appleton
Annette & Avram Bar-Cohen
Helen Beck
Lori & Robert Beck
Susan V. Bershad
Jennifer & Matthew Berzok
Carmella Bocchino
Amy Bonoff & Harris Jaffe
Donna Brogan
Alec Call & Bryan Johns
Maureen Calloway Carnevale
& Richard Carnevale
Chris & Delburn Carpenter
Carol & Richard Chadakoff
Paula Cleary
Jan R. Cloyde
Mary Ellen Colten
AnnaMaria DeSalva
Kay Dickersin & Robert Van Wesep
Elaine M. Dornig
Kate Dwyer
Sarah East
Dale & Harry Eastman
Ruth G. Eldredge
Beth Emery
Ileane & Irvin Fagin
Patricia Farren
Phyllis Fern
Silvia C. Formenti, MD
Liz & Richard Frank
Patricia L. Freysinger
Karren Ganstwig & Howard Welinsky
Terry Gillen
Dorian S. Goldman & Marvin Israelow
Katja Goldman & Michael Sonnenfeldt
Sherry Goldman
Victoria & Lloyd Goldman
Stephanie & Josh Goldstine
Anne & Tom Grant
Mindy & Jonathan Gray
Daniell T. Griffin
Greg Hannon
Sulabha V. Hardikar
Kathleen & Arthur Harris
Pat K. Haugen
Estate of Patricia Hayes
Giselle Hicks & William Ross
Ira Hillman & Jeremy Barber
Judi J. Hirshfield-Bartek & Elmer Bartek
Joanne M. Howes
Susan Johns
Angela Kaplan
Nancy Kaplan
Nancy F. Kearney
Thomas R. Kline
Harvey D. Kushner
Diane Senica Langley
Leona Laskin
Elaine & Michael Lasnik-Broida
Jason Liddell
Susan Love
Ngina Lythcott & Byllye Avery
Stewart Macaulay
Paula B. Markgraf
Janet & Joseph Marrinan
Carol Matyka
Michele May & David Walt
Marlene & Joseph McCarthy
Stephanie McConnell Trust
Diane E. McGarry
Jacqueline McMullen
Molly Mead
Catherine M. Meek
Alan Merson
Joy & John Moose
Pamela Morton
Gayle A. Nobbs
Melinda & Scott Nordeng
Peggy Northrop
Christine & Dermod Norton
John Noss & the Karin Decker Noss Trust
Darcie & Shelby Notkin
Norma & Norman Nutman
Rubina Oremus
Patricia Dawn Presnell
Michele Rakoff & Alan Sieroty
Spencer K. Raymond
Sylvia & Richard Rickard
Beverly D. Riola
Rosemary Rosso
Linda & Ken Rothweiler
Gay Rudis
Nancy A. Ryan
Arlene Sanford
Helen Schiff & Richard Congress
Estate of Hugh Schwartz
Donna Shalala
Joy A. Simha & Vasu Chari
Betty A. Sommer
Arleen F. Sorkin & Christopher Lloyd
Tracey & Shanin Specter
Sandra L. Spivey
Joan H. Strausberg
Fern & Lenard Tessler
Fran M. Visco & Arthur N. Brandolph
Carol & Terry Wall
Michael & Susan Weber
Carol A. Weiser
Marilyn Werner
Sandra K. Westfall
Maria Wetzel
Elizabeth Wohl
Ann C. Yahner
Beth Young
CORPORATE,
FOUNDATION &
ORGANIZATION
DONORS
2012
$500,000 AND ABOVE
Avon Foundation for Women
National Philanthropic Trust
$250,000 TO $499,999
Joyce & Irving Goldman Family Foundation
Vance Wall Foundation
$100,000 TO $249,999
Thinkway Toys
$50,000 TO $99,999
Amgen
Cancer International Research Group
Entertainment Industry Foundation
Innovative Skincare
Novartis Oncology
Revlon Group Foundation, Inc.
$25,000 TO $49,999
Eli Lilly & Company Corporate Affairs, LLC
Genentech, Inc.
Genomic Health, Inc.
Hearst Magazines
Longchamp USA, Inc.
North American Road Racing Association
The Sak Brand Group
Sanofi-aventis US, Inc.
Skadden, Arps, Slate, Meagher & Flom, LLP
$10,000 TO $24,999
American Express
BET Holdings
Bluegrass Films
Cancer Treatment Centers of America
Celgene
Condé Nast Publications
Cozen & O’Connor
ELLE Magazine
Ellie Shoes
Harper’s BAZAAR
HSNi, LLC
Illumination Entertainment
KPMG, LLP
Lifetime Television
Linear Technology Corporation
Mazda North American Operations
Mellam Family Foundation
Natixis North America, LLC
Oticon, Inc.
Pfizer, Inc.
Subway
TIME, Inc.
Translational Oncology Research
International, Inc.
Universal Partnerships & Licensing
Universal Studios
Viacom International, Inc.
Young & Rubicam
$5,000 TO $9,999
Alaska Breast Cancer Advocacy Partners
Alpha Factor
America’s Health Insurance Plans
The Anbinder Family Foundation
California Community Foundation
California Teachers Association
Carson-Dellosa Publishing, LLC
Clay Lacy Aviation
CRUMBS Bake Shop
The David Geffen Foundation
GE
The Glen & Mary Ann Charles
Family Foundation
Hasbro, Inc.
Hearthside Foods
Imagine Entertainment
James & Deborah Burrows Foundation
MediaLink
Meteor Group
Nestle Waters North America, Inc.
The Otis Booth Foundation
Richemont International SA
ZEFR
S2,500 TO $4,999
AD-LIB Apparel
Aon Foundation
AR Media
Breast Cancer Options, Inc.
The Broder Foundation
CBS Television Network
ColorMetrics, LLC
Delaware Breast Cancer Coalition, Inc.
Dr. Susan Love Research Foundation
Film 44
The Hargrove Pierce Foundation
Jerry D. Kayne & Ida Kayne Rev. Trust
Kayne Foundation
The Kennedy/Marshall Company
McDonald’s
NVG, LLC
Pitch
Rubie’s Costume Company, Inc.
Steve Tisch Family Foundation
Thorlos
TruLife
Violent Lips
Western Oregon University
Zissu Family Foundation
INDIVIDUAL
DONORS
2012
$20,000 AND ABOVE
Anonymous (1)
Alberto Cribiore
Estate of Patricia Hayes
Stephanie McConnell Trust
$10,000 TO $19,999
Anonymous (1)
Amy Bonoff & Harris Jaffe
Kate Dwyer
Patricia L. Freysinger
Mindy & Jonathan Gray
Thomas R. Kline
Susan Love
Christine & Dermod Norton
Michele Rakoff & Alan Sieroty
Arleen F. Sorkin & Christopher Lloyd
Fern & Lenard Tessler
Ann C. Yahner
$5,000 TO $9,999
Anonymous (2)
Susanna Lachs Adler & Dean Adler
Madeline & Stephen Anbinder
Lori & Robert Beck
Gerald Bernardi & Joe Keenan
Susan V. Bershad, MD
Noelle Cooke
Elaine M. Dornig
Patricia Farren
Paige & Scott Hornbacher
Karen Katen
Hugh Laurie
John Mahoney
Michele May & David Walt
John Noss & the Karin Decker Noss Trust
Darcie & Shelby Notkin
Donna Shalala
Tracey & Shanin Specter
Fran M. Visco & Arthur N. Brandolph
Pamela West
$2,500 TO $4,999
Anonymous (1)
Amy L. Applebaum
Debbie & Mark Attanasio
Carol & Richard Chadakoff
Sherry & Kenneth Corday
Terry Gillen
Sherry Goldman
Stephanie & Josh Goldstine
Susan and Robert Green
Judi J. Hirshfield-Bartek & Elmer Bartek
Janet Holden & Eric McCormack
Shari Kaufman
Carol Matyka
Molly Mead
Catherine M. Meek & Al Earle
Alan Merson
Pamela Morton
Jonathan Moss
Norma & Norman Nutman
Nancy A. Ryan
Arlene Sanford
Michael & Susan Weber
Margaret and Howard Weitzman
Maria Wetzel
2012
NBCC BOARD OF DIRECTORS
ALAMO BREAST CANCER FOUNDATION
Director: Joy Moose
Alternate: Jerry Worden
DELAWARE BREAST CANCER COALITION
Director: Vicky Cooke
Alternate: Rena Howard
BREAST CANCER ALLIANCE
OF GREATER CINCINNATI (BCA)
Director: Kathy Ball
Alternate: Ann Hernick
GEORGIA BREAST CANCER COALITION
FUND
Director: Ruth Eldredge
Alternate: Wendy Rohrssen
CABCO
Director: Sandy Walsh
Alternate: Michelle Rakoff
LINDA CREED
BREAST CANCER FOUNDATION
Director: Donna Duncan
Alternate: Linda Camerota
CEDAR SINAI BREAST CANCER
Director: Sherry Goldman
Alternate: Sylvia Estrada
CEDAR VALLEY CANCER CENTER:
BEYOND PINK TEAM
Director: Christine Carpenter
Alternate: Lori Seawel
COLORADO BREAST CANCER COALITION
Director: Vicki Tosher
Alternate: Darlene Matthews
NATIONAL WOMEN’S HEALTH NETWORK
Director: Cindy Pearson
Alternate: Amy Allina
NUEVA VIDA
Director: Larisa Caicedo
Alternate: Mary Jo Vazquez
RHODE ISLAND
BREAST CANCER COALITION
Director: Marlene McCarthy
Alternate: Jean Albert
SHARE
Director: Anne Grant
Alternate: Ivis Febus-Sampayo
DR. SUSAN LOVE
RESEARCH FOUNDATION
Director: Naz Sykes
Alternate: Judi Hirshfield-Bartek
VIRGINIA BREAST CANCER FOUNDATION
Director: Gay Rudis
Alternate: Meg Shrader
WISCONSIN BREAST CANCER COALITION
Director: Kathleen Harris
Alternate: Dawn Anderson METROPOLITAN WASHINGTON,
DC CHAPTER OF NBCC
Director: Christine Brunswick
Alternate: Rosemary Rosso
WOMEN OF COLOR BREAST CANCER
SURVIVOR’S SUPPORT PROJECT
Director: Shirley Brown
Alternate: Carolyn Tapp
MINNESOTA BREAST CANCER COALITION
Director: Christine Norton
YOUNG SURVIVAL COALITION
Director: Joy Simha
Alternate: Elizabeth Wohl
NATIONAL BREAST CANCER COALITION
President: Frances Visco
The National Breast Cancer Coalition Fund is a 501(c)(3) entity that
designs and runs programs to educate, train and inform advocates,
policy makers, scientists, providers and the public about science,
health care and advocacy; collaborates with the research community
on innovative research; effects change in the health care system to
advance access to quality health care for all and gives a powerful,
effective voice to breast cancer advocates everywhere.
The National Breast Cancer Coalition is a 501(c)(4) organization that
lobbies through its grassroots network for increased funding for
innovative research, a seat at the table to oversee how those funds
are spent and for public policies to expand access to quality health
care for all. The National Breast Cancer Coalition designs and works
to enact legislation, policy and regulation necessary to achieve its
mission to end breast cancer.
NBCC’s mission is to end breast cancer through action and advocacy.
1101 17th Street, NW, Suite 1300, Washington, DC 20036 | P 202.296.7477 | F 202.265.6854 | BreastCancer Deadline2020.org